KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbCellera Biologics (ABCL) Depreciation & Amortization (CF) (2020 - 2025)

Historic Depreciation & Amortization (CF) for AbCellera Biologics (ABCL) over the last 6 years, with Q3 2025 value amounting to $4.3 million.

  • AbCellera Biologics' Depreciation & Amortization (CF) rose 1315.79% to $4.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $15.3 million, marking a year-over-year increase of 705.59%. This contributed to the annual value of $12.5 million for FY2024, which is 205.47% down from last year.
  • Latest data reveals that AbCellera Biologics reported Depreciation & Amortization (CF) of $4.3 million as of Q3 2025, which was up 1315.79% from $4.5 million recorded in Q2 2025.
  • Over the past 5 years, AbCellera Biologics' Depreciation & Amortization (CF) peaked at $4.5 million during Q2 2025, and registered a low of $840000.0 during Q1 2021.
  • Its 5-year average for Depreciation & Amortization (CF) is $2.7 million, with a median of $2.9 million in 2023.
  • Its Depreciation & Amortization (CF) has fluctuated over the past 5 years, first soared by 11396.78% in 2022, then crashed by 4615.38% in 2024.
  • Quarter analysis of 5 years shows AbCellera Biologics' Depreciation & Amortization (CF) stood at $1.3 million in 2021, then surged by 113.97% to $2.8 million in 2022, then soared by 39.89% to $3.9 million in 2023, then crashed by 46.15% to $2.1 million in 2024, then surged by 104.76% to $4.3 million in 2025.
  • Its last three reported values are $4.3 million in Q3 2025, $4.5 million for Q2 2025, and $4.4 million during Q1 2025.